Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 4/20 | 0.40 |
| ▸ | GABRD | O14764 | 4/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.40 |
| ▸ | GABRE | P78334 | 4/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.40 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.40 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.40 |
| ▸ | GABRQ | Q9UN88 | 4/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21154504 | 0.96 | GABRP (0.40) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL21153959 | 0.93 | PIK3CD (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL21153988 | 0.89 | BAZ2B (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30506407 | 0.89 | FAAH (0.40) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL21114773 | 0.89 | FAAH (0.40) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL21153982 | 0.84 | BAZ2B (0.43) | — | |
| SCHEMBL22000215 | 0.83 | LMNA (0.43) | PDE3BPDE3ASMN1; SMN2 | |
| SCHEMBL21162620 | 0.82 | BAZ2B (0.42) | — | |
| SCHEMBL21588406 | 0.82 | PIK3CD (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL25680636 | 0.82 | PIK3CD (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3735411-B1 | 1,3,4,5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER`S DISEASE | AC IMMUNE SA (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| US-20200148679-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2020-05-14 | — | — | US | disclosed |
| US-10633383-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2020-04-28 | — | — | US | disclosed |
| US-20190211012-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2019-07-11 | — | — | US | disclosed |
| WO-2019134978-A1 | 1, 3, 4, 5-TETRAHYDRO-2H-PYRIDO[4,3-B]INDOLE DERIVATIVES FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES LIKE ALZHEIMER'S DISEASE | AC IMMUNE SA (CH) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190211012-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, MAP1LC3B | GABRP 1947/4885GABRD 2485/4885GABRA1 1732/4885 |
| US-10633383-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | GABRP 2324/4885GABRD 2562/4885GABRA1 1927/4885 |
| US-20200148679-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, MAP1LC3B | GABRP 1947/4885GABRD 2485/4885GABRA1 1732/4885 |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | GABRP 2324/4885GABRD 2562/4885GABRA1 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.